CBTCabot Corporation

$84.59

Is the price fair?

What CBT's price assumes

Cabot Corporation trades at 16.0× earnings against 28.3× for the median Specialty Chemicals name, cheaper than its own group.

16.0

Trailing P/E · Specialty Chemicals median 28.3 · cheaper than the typical name in its group

Price / sales
1.09

Price / sales · as of 2026-Q1

Free cash flow yield
9.1%

Free cash flow yield · Specialty Chemicals median 3.9%

Growth the price implies
−2.4%

Growth the price implies · The price pays for −2.4% free cash flow growth a year for a decade; the business has delivered +50% a year over the last three.

Details
Price / book2026-Q1
2.49
EV / EBIT2026-Q1
8.04
EV / sales2026-Q1
1.26
Basic Materials median P/E153 names
22.8
Specialty Chemicals median P/E37 names
28.3
Free cash flow, trailing twelve months
$432M
Market capitalisation
$4.74B
3-year revenue growth
−5.7%
3-year free cash flow growth
+50%
What the market has paid for these earnings: 24 quarters of its own multiple × $5.30 of trailing earnings per share
MethodPer share
Its own P/E history, lower quartile$61.91
Its own P/E history, median$66.78
Its own P/E history, upper quartile$82.83
52-week range$57.64 – $93.09
Today$84.59

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.